Trials / Unknown
UnknownNCT05805943
Study of IMM0306 in Patients With Relapsed or Refractory CD20-positive B-cell Non-Hodgkin's Lymphoma
Phase I/II Study of IMM0306 in Patients With Relapsed or Refractory CD20-positive B-cell Non-Hodgkin's Lymphoma
- Status
- Unknown
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 154 (estimated)
- Sponsor
- ImmuneOnco Biopharmaceuticals (Shanghai) Inc. · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase I/II, Single-Arm, Open-Label, Multicentre Study to Evaluate the Safety and Efficacy of IMM0306 in Patients with Relapsed or Refractory B-Cell Non- Hodgkin's Lymphoma (R/R B-NHL).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | IMM0306 | IMM0306 is an bi-specific antibody |
Timeline
- Start date
- 2020-03-02
- Primary completion
- 2025-05-25
- Completion
- 2025-05-25
- First posted
- 2023-04-10
- Last updated
- 2023-04-10
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05805943. Inclusion in this directory is not an endorsement.